Asthma Drugs Market to Reach USD 41.18 Billion by 2035 | Biologic Therapies Accelerate Shift Toward Targeted Treatment Says Astute Analytica
View original at finance.yahoo.com“This momentum continued into the fourth quarter, where sales reached EUR 3,458 million (USD 3,800 million).”
Lo que extrajimos de esta fuente
The claims Via News extracted from this document. We point to the source; we don't replace it.
North America dominated the global market, accounting for the largest share of 47% in 2025
80% confidenceThe market is bifurcating, with innovation focused on severe phenotypes and smart delivery, while policy shifts mandate affordability for mass-market generic access
80% confidenceAsthma accounts for 1.4 million emergency department visits and 94,000 hospital inpatient stays annually in the US
80% confidenceThe direct cost of asthma care is estimated at USD 3,728 per person annually
80% confidence3,517 asthma deaths were reported in the most recent US data
80% confidenceHigh-value biologic therapies are overtaking traditional treatments, driving revenue despite pricing pressures on standard inhalers
80% confidenceIndia reports 34 million asthma cases, creating massive demand for affordable generic inhalers
80% confidenceThe global smart inhaler market was valued at USD 1.53 billion in 2024 and could reach USD 7.9 billion by 2030
80% confidenceChina's Volume-Based Procurement (VBP) has slashed generic prices by ~50%, forcing multinationals to abandon legacy generic margins in favor of introducing innovative biologics to the self-pay and private insurance tiers
80% confidenceThe FDA approved 50 novel drugs in 2024
80% confidenceThe global asthma drugs market size was valued at USD 26.52 billion in 2025 and is projected to hit the market valuation of USD 41.18 billion by 2035 at a CAGR of 4.50% during the forecast period 2026–2035
80% confidenceThere are 4.7 million children with asthma in the US, contributing to a total affected population of 24.9 million
80% confidence